144 related articles for article (PubMed ID: 31805192)
1. Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias.
Sridharan A; Schinke CD; Georgiev G; Da Silva Ferreira M; Thiruthuvanathan V; MacArthur I; Bhagat TD; Choudhary GS; Aluri S; Chen J; Pradhan K; Xia Y; Panjikaran M; Sims G; Bhagat CK; Bender R; Keeler L; Graber A; Heuck C; Fletcher FA; Alapat D; Weinhold N; Johnson SK; Wickrema A; Barlogie B; Morgan GJ; Shastri A; Steidl U; Will B; Verma A
Blood Adv; 2019 Dec; 3(23):3962-3967. PubMed ID: 31805192
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia.
Pemmaraju N; Shah D; Kantarjian H; Orlowski RZ; Nogueras González GM; Baladandayuthapani V; Jain N; Wagner V; Garcia-Manero G; Shah J; Ravandi F; Pierce S; Takahashi K; Daver N; Nazha A; Verstovsek S; Jabbour E; De Lima M; Champlin R; Cortes J; Qazilbash MH
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):110-4. PubMed ID: 25107338
[TBL] [Abstract][Full Text] [Related]
3. Diagnosing therapy-related acute myeloid leukemia with 8% blasts in bone marrow with concomitant plasma cell myeloma.
Thakral B; Muzzafar T
Blood; 2017 Jul; 130(2):231. PubMed ID: 28705862
[No Abstract] [Full Text] [Related]
4. Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study.
Jonsdottir G; Lund SH; Björkholm M; Turesson I; Wahlin A; Mailankody S; Blimark C; Hultcrantz M; Porwit A; Landgren O; Kristinsson SY
Haematologica; 2016 Apr; 101(4):e145-8. PubMed ID: 26681760
[No Abstract] [Full Text] [Related]
5. The incidence of secondary leukemias.
Leone G; Mele L; Pulsoni A; Equitani F; Pagano L
Haematologica; 1999 Oct; 84(10):937-45. PubMed ID: 10509043
[TBL] [Abstract][Full Text] [Related]
6. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.
Wong TN; Ramsingh G; Young AL; Miller CA; Touma W; Welch JS; Lamprecht TL; Shen D; Hundal J; Fulton RS; Heath S; Baty JD; Klco JM; Ding L; Mardis ER; Westervelt P; DiPersio JF; Walter MJ; Graubert TA; Ley TJ; Druley T; Link DC; Wilson RK
Nature; 2015 Feb; 518(7540):552-555. PubMed ID: 25487151
[TBL] [Abstract][Full Text] [Related]
7. Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens.
Reddi DM; Lu CM; Fedoriw G; Liu YC; Wang FF; Ely S; Boswell EL; Louissaint A; Arcasoy MO; Goodman BK; Wang E
Am J Clin Pathol; 2012 Dec; 138(6):855-66. PubMed ID: 23161720
[TBL] [Abstract][Full Text] [Related]
8. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
10. Cytogenetically unrelated clones in therapy-related myelodysplasia and acute myeloid leukemia: experience from the Copenhagen series updated to 180 consecutive cases.
Pedersen-Bjergaard J; Timshel S; Andersen MK; Andersen AS; Philip P
Genes Chromosomes Cancer; 1998 Dec; 23(4):337-49. PubMed ID: 9824207
[TBL] [Abstract][Full Text] [Related]
11. Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience.
Aguilera DG; Vaklavas C; Tsimberidou AM; Wen S; Medeiros LJ; Corey SJ
J Pediatr Hematol Oncol; 2009 Nov; 31(11):803-11. PubMed ID: 19801947
[TBL] [Abstract][Full Text] [Related]
12. Clonal Hematopoiesis and therapy related MDS/AML.
Desai P; Roboz GJ
Best Pract Res Clin Haematol; 2019 Mar; 32(1):13-23. PubMed ID: 30927970
[TBL] [Abstract][Full Text] [Related]
13. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
[TBL] [Abstract][Full Text] [Related]
14. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
15. A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma.
Jang GD; Kim SW; Suh CW; Kim EK; Bahng HS; Jeong YH; Park IG; Kim WK; Kim SH; Suh EJ; Park CJ; Ji HS; Lee JS
J Korean Med Sci; 2002 Aug; 17(4):555-9. PubMed ID: 12172056
[TBL] [Abstract][Full Text] [Related]
16. Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia.
Majeti R
Best Pract Res Clin Haematol; 2014; 27(3-4):229-34. PubMed ID: 25455271
[TBL] [Abstract][Full Text] [Related]
17. Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes.
Stevens BM; Khan N; D'Alessandro A; Nemkov T; Winters A; Jones CL; Zhang W; Pollyea DA; Jordan CT
Nat Commun; 2018 Sep; 9(1):3694. PubMed ID: 30209285
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation.
Gilliland DG; Gribben JG
Biol Blood Marrow Transplant; 2002; 8(1):9-16. PubMed ID: 11846355
[TBL] [Abstract][Full Text] [Related]
19. Are growth factors leukemogenic?
Brodsky RA; Bedi A; Jones RJ
Leukemia; 1996 Jan; 10(1):175-7. PubMed ID: 8558925
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
